PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1135
https://www.valueinhealthjournal.com/article/S1098-3015(19)33513-2/fulltext
Title :
PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33513-2&doi=10.1016/j.jval.2019.09.1135
First page :
Section Title :
Open access? :
No
Section Order :
10994